Evidence map›Paper›PMID 41416931›Full record

ReviewEuropean journal of immunology2025

Decoding the Cryptic Proteome Between Antigens and Novel Functional Proteins.

Emma G Bawden, Sebastian Amigorena, Yago A Arribas

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Emma G BawdenInserm U932 Immunity and Cancer, Institut Curie, PSL University, Paris, 75005, France.
Sebastian AmigorenaInserm U932 Immunity and Cancer, Institut Curie, PSL University, Paris, 75005, France.
Yago A ArribasInserm U932 Immunity and Cancer, Institut Curie, PSL University, Paris, 75005, France.ORCID 0000-0003-4434-3075

Funding

Agence Nationale de la Recherche ANR-10-IDEX-0001-02-PSLAgence Nationale de la Recherche ANR11-LABX-0043Agence Nationale de la Recherche ANR-16CE1500180Agence Nationale de la Recherche ANR-16CE18002003Agence Nationale de la Recherche ANR-21-RHUS-0016(EpCART)Agence Nationale de la Recherche ANR-22CE44001403Center for Clinical Investigation IGR-Curie1428European Union CEIMI821558IMMUCAN
6 · The paper itself

Abstract

The widespread translation of cryptic proteins derived from the non-coding genome expands the complexity of the human proteome. A vast majority of cryptic proteins are expressed at low levels, rapidly degraded and efficiently presented on class I major histocompatibility complexes (MHC-I). On the other hand, some cryptic proteins are stable and functional and may integrate into the proteome through ongoing selective pressures. Herein, we propose a model in which the translation of cryptic proteins increases the diversity of functional proteins on which evolution can act and, during this trial-and-error process, provides a valuable source of antigens for immunosurveillance.

Indexed as

AntigensHistocompatibility Antigens Class IProteomeAnimalsAntigen PresentationEvolution, MolecularHumansProtein BiosynthesisAntigensHistocompatibility Antigens Class IProteomeantigen presentationcryptic proteomeDRiPsimmunopeptidomicsribosome profiling

Identifiers

PMID41416931
PMCPMC12716223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.